Nat Genet:一基因变异可增加黑素瘤发病风险

2014-04-03 健康报 健康报

一个国际团队最新研究发现,一种基因变异可增加黑素瘤发病风险。新发现有助于医学界开发出防治这种恶性皮肤癌的更有效方法。 这项研究由英国、荷兰、澳大利亚和美国等国研究人员共同完成,研究结果发表在英国新一期《自然·遗传学》杂志上。研究人员对184名黑素瘤患者进行了基因测序,结果发现,名为POT1的基因如出现变异会显着增加患上黑素瘤的风险。 分析显示,该基因变异会抑制与之相应的蛋白质发挥作用,而这种蛋

一个国际团队最新研究发现,一种基因变异可增加黑素瘤发病风险。新发现有助于医学界开发出防治这种恶性皮肤癌的更有效方法。

这项研究由英国、荷兰、澳大利亚和美国等国研究人员共同完成,研究结果发表在英国新一期《自然·遗传学》杂志上。研究人员对184名黑素瘤患者进行了基因测序,结果发现,名为POT1的基因如出现变异会显着增加患上黑素瘤的风险。

分析显示,该基因变异会抑制与之相应的蛋白质发挥作用,而这种蛋白质的主要功能就是保护染色体,防止其受损。皮肤癌等癌症与染色体受损有密切联系。

进一步研究发现,带有这种基因变异的家族出现白血病等其他类型癌症的几率也高于正常水平,这可能预示着该变异与其他类型癌症的患病风险也有关联。

参与研究的英国桑格研究所研究员戴维·亚当斯说,这一发现不仅有助于对黑素瘤这种难治癌症进行风险筛查,未来还有望将这种基因变异作为治疗靶点,开发出有效的治疗方法。

黑素瘤是由于皮肤中的色素细胞发生病变而引起的一种癌症。据统计,最近30年全球黑素瘤发病率上升4倍,但一直缺乏有效的治疗药物。此前研究发现,黑素瘤发病风险与日光照射、皮肤类型和家族病史等有关。

原始出处:

Robles-Espinoza CD1, Harland M2, Ramsay AJ3, Aoude LG4, Quesada V5, Ding Z6, Pooley KA7, Pritchard AL8, Tiffen JC6, Petljak M6, Palmer JM8, Symmons J8, Johansson P8, Stark MS8, Gartside MG8, Snowden H9, Montgomery GW10, Martin NG11, Liu JZ12, Choi J13, Makowski M13, Brown KM13, Dunning AM14, Keane TM6, López-Otín C5, Gruis NA15, Hayward NK4, Bishop DT2, Newton-Bishop JA2, Adams DJ1.POT1 loss-of-function variants predispose to familial melanoma.Nat Genet. 2014 Mar 30. doi: 10.1038/ng.2947.

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (7)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=2048580, encodeId=d2112048580db, content=<a href='/topic/show?id=4363e929ad' target=_blank style='color:#2F92EE;'>#Gene#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7929, encryptionId=4363e929ad, topicName=Gene)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=63a4277, createdName=cy0324, createdTime=Sat May 24 01:59:00 CST 2014, time=2014-05-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1879998, encodeId=856218e9998f9, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Sat Apr 19 00:59:00 CST 2014, time=2014-04-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1685934, encodeId=78cd1685934b0, content=<a href='/topic/show?id=66f3e93862' target=_blank style='color:#2F92EE;'>#Genet#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7938, encryptionId=66f3e93862, topicName=Genet)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d3e128296421, createdName=江川靖瑶, createdTime=Mon Apr 07 14:59:00 CST 2014, time=2014-04-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1733679, encodeId=95cf1e336790e, content=<a href='/topic/show?id=d4f412668a4' target=_blank style='color:#2F92EE;'>#NET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12668, encryptionId=d4f412668a4, topicName=NET)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7ea033781210, createdName=canlab, createdTime=Tue Mar 17 14:59:00 CST 2015, time=2015-03-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1314126, encodeId=4f661314126b0, content=<a href='/topic/show?id=b5e641e1279' target=_blank style='color:#2F92EE;'>#基因变异#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=41712, encryptionId=b5e641e1279, topicName=基因变异)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=512d422, createdName=canlab, createdTime=Sat Apr 05 02:59:00 CST 2014, time=2014-04-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1342297, encodeId=4413134229e5f, content=<a href='/topic/show?id=34cb381023e' target=_blank style='color:#2F92EE;'>#变异#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=38102, encryptionId=34cb381023e, topicName=变异)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=78c32500188, createdName=12498dabm77暂无昵称, createdTime=Sat Apr 05 02:59:00 CST 2014, time=2014-04-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1479403, encodeId=befc14e9403ae, content=<a href='/topic/show?id=4a571033209b' target=_blank style='color:#2F92EE;'>#黑素瘤#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=103320, encryptionId=4a571033209b, topicName=黑素瘤)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4d4d7523220, createdName=yuhaisheng_ibp_32061713, createdTime=Sat Apr 05 02:59:00 CST 2014, time=2014-04-05, status=1, ipAttribution=)]
    2014-05-24 cy0324
  2. [GetPortalCommentsPageByObjectIdResponse(id=2048580, encodeId=d2112048580db, content=<a href='/topic/show?id=4363e929ad' target=_blank style='color:#2F92EE;'>#Gene#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7929, encryptionId=4363e929ad, topicName=Gene)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=63a4277, createdName=cy0324, createdTime=Sat May 24 01:59:00 CST 2014, time=2014-05-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1879998, encodeId=856218e9998f9, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Sat Apr 19 00:59:00 CST 2014, time=2014-04-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1685934, encodeId=78cd1685934b0, content=<a href='/topic/show?id=66f3e93862' target=_blank style='color:#2F92EE;'>#Genet#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7938, encryptionId=66f3e93862, topicName=Genet)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d3e128296421, createdName=江川靖瑶, createdTime=Mon Apr 07 14:59:00 CST 2014, time=2014-04-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1733679, encodeId=95cf1e336790e, content=<a href='/topic/show?id=d4f412668a4' target=_blank style='color:#2F92EE;'>#NET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12668, encryptionId=d4f412668a4, topicName=NET)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7ea033781210, createdName=canlab, createdTime=Tue Mar 17 14:59:00 CST 2015, time=2015-03-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1314126, encodeId=4f661314126b0, content=<a href='/topic/show?id=b5e641e1279' target=_blank style='color:#2F92EE;'>#基因变异#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=41712, encryptionId=b5e641e1279, topicName=基因变异)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=512d422, createdName=canlab, createdTime=Sat Apr 05 02:59:00 CST 2014, time=2014-04-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1342297, encodeId=4413134229e5f, content=<a href='/topic/show?id=34cb381023e' target=_blank style='color:#2F92EE;'>#变异#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=38102, encryptionId=34cb381023e, topicName=变异)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=78c32500188, createdName=12498dabm77暂无昵称, createdTime=Sat Apr 05 02:59:00 CST 2014, time=2014-04-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1479403, encodeId=befc14e9403ae, content=<a href='/topic/show?id=4a571033209b' target=_blank style='color:#2F92EE;'>#黑素瘤#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=103320, encryptionId=4a571033209b, topicName=黑素瘤)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4d4d7523220, createdName=yuhaisheng_ibp_32061713, createdTime=Sat Apr 05 02:59:00 CST 2014, time=2014-04-05, status=1, ipAttribution=)]
    2014-04-19 liye789132251
  3. [GetPortalCommentsPageByObjectIdResponse(id=2048580, encodeId=d2112048580db, content=<a href='/topic/show?id=4363e929ad' target=_blank style='color:#2F92EE;'>#Gene#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7929, encryptionId=4363e929ad, topicName=Gene)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=63a4277, createdName=cy0324, createdTime=Sat May 24 01:59:00 CST 2014, time=2014-05-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1879998, encodeId=856218e9998f9, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Sat Apr 19 00:59:00 CST 2014, time=2014-04-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1685934, encodeId=78cd1685934b0, content=<a href='/topic/show?id=66f3e93862' target=_blank style='color:#2F92EE;'>#Genet#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7938, encryptionId=66f3e93862, topicName=Genet)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d3e128296421, createdName=江川靖瑶, createdTime=Mon Apr 07 14:59:00 CST 2014, time=2014-04-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1733679, encodeId=95cf1e336790e, content=<a href='/topic/show?id=d4f412668a4' target=_blank style='color:#2F92EE;'>#NET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12668, encryptionId=d4f412668a4, topicName=NET)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7ea033781210, createdName=canlab, createdTime=Tue Mar 17 14:59:00 CST 2015, time=2015-03-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1314126, encodeId=4f661314126b0, content=<a href='/topic/show?id=b5e641e1279' target=_blank style='color:#2F92EE;'>#基因变异#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=41712, encryptionId=b5e641e1279, topicName=基因变异)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=512d422, createdName=canlab, createdTime=Sat Apr 05 02:59:00 CST 2014, time=2014-04-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1342297, encodeId=4413134229e5f, content=<a href='/topic/show?id=34cb381023e' target=_blank style='color:#2F92EE;'>#变异#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=38102, encryptionId=34cb381023e, topicName=变异)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=78c32500188, createdName=12498dabm77暂无昵称, createdTime=Sat Apr 05 02:59:00 CST 2014, time=2014-04-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1479403, encodeId=befc14e9403ae, content=<a href='/topic/show?id=4a571033209b' target=_blank style='color:#2F92EE;'>#黑素瘤#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=103320, encryptionId=4a571033209b, topicName=黑素瘤)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4d4d7523220, createdName=yuhaisheng_ibp_32061713, createdTime=Sat Apr 05 02:59:00 CST 2014, time=2014-04-05, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=2048580, encodeId=d2112048580db, content=<a href='/topic/show?id=4363e929ad' target=_blank style='color:#2F92EE;'>#Gene#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7929, encryptionId=4363e929ad, topicName=Gene)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=63a4277, createdName=cy0324, createdTime=Sat May 24 01:59:00 CST 2014, time=2014-05-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1879998, encodeId=856218e9998f9, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Sat Apr 19 00:59:00 CST 2014, time=2014-04-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1685934, encodeId=78cd1685934b0, content=<a href='/topic/show?id=66f3e93862' target=_blank style='color:#2F92EE;'>#Genet#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7938, encryptionId=66f3e93862, topicName=Genet)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d3e128296421, createdName=江川靖瑶, createdTime=Mon Apr 07 14:59:00 CST 2014, time=2014-04-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1733679, encodeId=95cf1e336790e, content=<a href='/topic/show?id=d4f412668a4' target=_blank style='color:#2F92EE;'>#NET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12668, encryptionId=d4f412668a4, topicName=NET)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7ea033781210, createdName=canlab, createdTime=Tue Mar 17 14:59:00 CST 2015, time=2015-03-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1314126, encodeId=4f661314126b0, content=<a href='/topic/show?id=b5e641e1279' target=_blank style='color:#2F92EE;'>#基因变异#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=41712, encryptionId=b5e641e1279, topicName=基因变异)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=512d422, createdName=canlab, createdTime=Sat Apr 05 02:59:00 CST 2014, time=2014-04-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1342297, encodeId=4413134229e5f, content=<a href='/topic/show?id=34cb381023e' target=_blank style='color:#2F92EE;'>#变异#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=38102, encryptionId=34cb381023e, topicName=变异)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=78c32500188, createdName=12498dabm77暂无昵称, createdTime=Sat Apr 05 02:59:00 CST 2014, time=2014-04-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1479403, encodeId=befc14e9403ae, content=<a href='/topic/show?id=4a571033209b' target=_blank style='color:#2F92EE;'>#黑素瘤#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=103320, encryptionId=4a571033209b, topicName=黑素瘤)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4d4d7523220, createdName=yuhaisheng_ibp_32061713, createdTime=Sat Apr 05 02:59:00 CST 2014, time=2014-04-05, status=1, ipAttribution=)]
    2015-03-17 canlab
  5. [GetPortalCommentsPageByObjectIdResponse(id=2048580, encodeId=d2112048580db, content=<a href='/topic/show?id=4363e929ad' target=_blank style='color:#2F92EE;'>#Gene#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7929, encryptionId=4363e929ad, topicName=Gene)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=63a4277, createdName=cy0324, createdTime=Sat May 24 01:59:00 CST 2014, time=2014-05-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1879998, encodeId=856218e9998f9, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Sat Apr 19 00:59:00 CST 2014, time=2014-04-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1685934, encodeId=78cd1685934b0, content=<a href='/topic/show?id=66f3e93862' target=_blank style='color:#2F92EE;'>#Genet#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7938, encryptionId=66f3e93862, topicName=Genet)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d3e128296421, createdName=江川靖瑶, createdTime=Mon Apr 07 14:59:00 CST 2014, time=2014-04-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1733679, encodeId=95cf1e336790e, content=<a href='/topic/show?id=d4f412668a4' target=_blank style='color:#2F92EE;'>#NET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12668, encryptionId=d4f412668a4, topicName=NET)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7ea033781210, createdName=canlab, createdTime=Tue Mar 17 14:59:00 CST 2015, time=2015-03-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1314126, encodeId=4f661314126b0, content=<a href='/topic/show?id=b5e641e1279' target=_blank style='color:#2F92EE;'>#基因变异#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=41712, encryptionId=b5e641e1279, topicName=基因变异)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=512d422, createdName=canlab, createdTime=Sat Apr 05 02:59:00 CST 2014, time=2014-04-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1342297, encodeId=4413134229e5f, content=<a href='/topic/show?id=34cb381023e' target=_blank style='color:#2F92EE;'>#变异#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=38102, encryptionId=34cb381023e, topicName=变异)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=78c32500188, createdName=12498dabm77暂无昵称, createdTime=Sat Apr 05 02:59:00 CST 2014, time=2014-04-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1479403, encodeId=befc14e9403ae, content=<a href='/topic/show?id=4a571033209b' target=_blank style='color:#2F92EE;'>#黑素瘤#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=103320, encryptionId=4a571033209b, topicName=黑素瘤)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4d4d7523220, createdName=yuhaisheng_ibp_32061713, createdTime=Sat Apr 05 02:59:00 CST 2014, time=2014-04-05, status=1, ipAttribution=)]
  6. [GetPortalCommentsPageByObjectIdResponse(id=2048580, encodeId=d2112048580db, content=<a href='/topic/show?id=4363e929ad' target=_blank style='color:#2F92EE;'>#Gene#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7929, encryptionId=4363e929ad, topicName=Gene)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=63a4277, createdName=cy0324, createdTime=Sat May 24 01:59:00 CST 2014, time=2014-05-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1879998, encodeId=856218e9998f9, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Sat Apr 19 00:59:00 CST 2014, time=2014-04-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1685934, encodeId=78cd1685934b0, content=<a href='/topic/show?id=66f3e93862' target=_blank style='color:#2F92EE;'>#Genet#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7938, encryptionId=66f3e93862, topicName=Genet)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d3e128296421, createdName=江川靖瑶, createdTime=Mon Apr 07 14:59:00 CST 2014, time=2014-04-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1733679, encodeId=95cf1e336790e, content=<a href='/topic/show?id=d4f412668a4' target=_blank style='color:#2F92EE;'>#NET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12668, encryptionId=d4f412668a4, topicName=NET)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7ea033781210, createdName=canlab, createdTime=Tue Mar 17 14:59:00 CST 2015, time=2015-03-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1314126, encodeId=4f661314126b0, content=<a href='/topic/show?id=b5e641e1279' target=_blank style='color:#2F92EE;'>#基因变异#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=41712, encryptionId=b5e641e1279, topicName=基因变异)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=512d422, createdName=canlab, createdTime=Sat Apr 05 02:59:00 CST 2014, time=2014-04-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1342297, encodeId=4413134229e5f, content=<a href='/topic/show?id=34cb381023e' target=_blank style='color:#2F92EE;'>#变异#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=38102, encryptionId=34cb381023e, topicName=变异)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=78c32500188, createdName=12498dabm77暂无昵称, createdTime=Sat Apr 05 02:59:00 CST 2014, time=2014-04-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1479403, encodeId=befc14e9403ae, content=<a href='/topic/show?id=4a571033209b' target=_blank style='color:#2F92EE;'>#黑素瘤#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=103320, encryptionId=4a571033209b, topicName=黑素瘤)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4d4d7523220, createdName=yuhaisheng_ibp_32061713, createdTime=Sat Apr 05 02:59:00 CST 2014, time=2014-04-05, status=1, ipAttribution=)]
  7. [GetPortalCommentsPageByObjectIdResponse(id=2048580, encodeId=d2112048580db, content=<a href='/topic/show?id=4363e929ad' target=_blank style='color:#2F92EE;'>#Gene#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7929, encryptionId=4363e929ad, topicName=Gene)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=63a4277, createdName=cy0324, createdTime=Sat May 24 01:59:00 CST 2014, time=2014-05-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1879998, encodeId=856218e9998f9, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Sat Apr 19 00:59:00 CST 2014, time=2014-04-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1685934, encodeId=78cd1685934b0, content=<a href='/topic/show?id=66f3e93862' target=_blank style='color:#2F92EE;'>#Genet#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7938, encryptionId=66f3e93862, topicName=Genet)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d3e128296421, createdName=江川靖瑶, createdTime=Mon Apr 07 14:59:00 CST 2014, time=2014-04-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1733679, encodeId=95cf1e336790e, content=<a href='/topic/show?id=d4f412668a4' target=_blank style='color:#2F92EE;'>#NET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12668, encryptionId=d4f412668a4, topicName=NET)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7ea033781210, createdName=canlab, createdTime=Tue Mar 17 14:59:00 CST 2015, time=2015-03-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1314126, encodeId=4f661314126b0, content=<a href='/topic/show?id=b5e641e1279' target=_blank style='color:#2F92EE;'>#基因变异#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=41712, encryptionId=b5e641e1279, topicName=基因变异)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=512d422, createdName=canlab, createdTime=Sat Apr 05 02:59:00 CST 2014, time=2014-04-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1342297, encodeId=4413134229e5f, content=<a href='/topic/show?id=34cb381023e' target=_blank style='color:#2F92EE;'>#变异#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=38102, encryptionId=34cb381023e, topicName=变异)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=78c32500188, createdName=12498dabm77暂无昵称, createdTime=Sat Apr 05 02:59:00 CST 2014, time=2014-04-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1479403, encodeId=befc14e9403ae, content=<a href='/topic/show?id=4a571033209b' target=_blank style='color:#2F92EE;'>#黑素瘤#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=103320, encryptionId=4a571033209b, topicName=黑素瘤)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4d4d7523220, createdName=yuhaisheng_ibp_32061713, createdTime=Sat Apr 05 02:59:00 CST 2014, time=2014-04-05, status=1, ipAttribution=)]

相关资讯

王华明:肿瘤急症处理可多用微创

肿瘤在其自然发展病程或治疗过程中,均会出现危及患者生命、需紧急处理的情况,业内专家日前指出,对这些肿瘤相关急症的及时识别和迅速得当处理关乎患者生命,医务人员应强化对肿瘤急症的认识。 日前,中国抗癌协会肿瘤微创治疗专业委员会肿瘤急症微创治疗分会暨第一届肿瘤急症微创治疗高峰论坛在京举行。该分会副主任委员、解放军第302医院介入科主任王华明教授提出上述观点。 王华

Cell Rep:PTEN基因特定区域可抑制肿瘤

北京大学基础医学院尹玉新教授课题组研究发现,PTEN基因特定区域在维持基因组稳定性,抑制肿瘤发生发展中具有重要作用。相关研究论文日前发表在《细胞》杂志新子刊《细胞报告》上。 尹玉新介绍,PTEN基因是人类肿瘤中突变率仅次于p53(抗癌基因)的强大抗癌基因,在多种类型的癌症中都存在PTEN基因突变或缺失。PTEN突变或表达异常与癌细胞的生长、黏附、迁移、浸润等密切相关

Theranostics:肿瘤靶向诊断与治疗研究取得进展

恶性肿瘤是严重威胁人类健康的疾病之一。近年来,恶性肿瘤的发病率和死亡率均呈明显升高趋势,因此针对恶性肿瘤的靶向诊断与治疗具有十分重要的现实意义。 在国家自然科学基金、福建省自然科学基金等项目的支持下,中国科学院福建物质结构研究所结构化学国家重点实验室黄明东课题组和陈学元课题组在结构生物学、光动力学、生物光学领域长期研究积累基础上,利用基因重组技术,构建了一种新型的具有肿瘤靶向性的融合蛋白药物载体

转化医学:开启肿瘤治疗新契机——2014肿瘤转化医学国际研讨会

近年来,随着基因组学、功能基因组学和结构基因组学等重大医学进展以及生物信息学在生命科学领域的广泛应用,基础医学研究得到了巨大进步及辉煌成就,然而如何使大量的研究成果转化为临床应用仍是尚未解决的难题。转化医学是近十年来国际生物医学领域出现的新概念和重点研究方向,其宗旨就是打破基础科学和临床科学、药物研发以及医疗器械的研制之间的屏障,缩短实验室到病床的过程,使患者能够尽早享受到最新的科研成果,推动医学

肿瘤防治 “生物钟”能帮上忙吗

跟花草树木“一岁一枯荣”一样,人体生命活动也有独特的时间节奏。将生命活动的时间性特点整合到疾病防治中的时间医学,是当下国际生命科学研究领域的一大热点。中山大学肿瘤防治中心冼励坚教授领衔的科研团队历时10年探索,将时间医学应用于肿瘤防治,为我国肿瘤防治推开了一扇新窗口。相关研究成果近日获得2013年度中华医学科技奖三等奖。 时钟基因与肿瘤生长密切相关 “基于生

NEJM病例:腮腺肿瘤引起的扁桃体不对称

该病例发表在2014年3月27日刊《新英格兰医学杂志》上。 女,28岁,平素健康,因近期发现扁桃体不对称求诊。其左侧脸颊有一细小的无痛性肿物,并在过去数月间缓慢增大。查体发现左侧扁桃体向中线移位(图A,箭头),并证实左下颌后区域内有一质硬、不可推动的肿物。无颈淋巴结肿大或面神经异常。T2加权的核磁共振成像(MRI)可见左侧腮腺有一高密度肿瘤(图B,冠状位,箭头),大小约为6 cm×4